neuropeptide Y receptor Y6 (pseudogene)Genealiases: []
Q-omics provides the consensus-scored NPY6R profile across patient tissues and cancer cell-line models. NPY6R expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NPY6R is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, NPY6R RNA expression shows 15,481 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, COAD, and TGCT as cancer lineages where NPY6R shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NPY6R — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NPY6R survival associations across molecular data types. NPY6R RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NPY6R RNA expression–survival associations across cancer types. High NPY6R expression shows unfavorable associations in MESO, but favorable associations in KIRC, COAD, ACC, SKCM and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NPY6R RNA expression.
This table summarizes NPY6R tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for NPY6R. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NPY6R shows lower tumor expression in COAD, BLCA, HNSC, LUSC and UCEC and higher tumor expression in KIRC. The COAD box plot shows higher NPY6R RNA expression in normal versus tumor tissue (log2 FC = −2.644, t-test p < 0.001).
This table shows molecular features associated with NPY6R in patient tissues and cancer cell lines. In patient samples, NPY6R shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, NPY6R RNA and mutation anchors are most strongly linked to RNA-expression features, especially in NCI60_ALL.
